darolutamide
Sponsor AZN · listed as AZN
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-12-31
As disclosedDec 2026
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT03903835
PhasePHASE3
StatusRECRUITING
Lead sponsorKarolinska Institutet
Listed asAZN
Condition(s)Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
All tracked catalysts for darolutamide
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-12-31 | READOUT | medium | NCT03903835 |
| 2027-07-30 | READOUT | medium | NCT05794906 |
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More AZN catalysts